Intravenous Artesunate Reduces Parasite Clearance Time, Duration of Intensive Care, and Hospital Treatment in Patients With Severe Malaria in Europe: The TropNet Severe Malaria Study: Figure 1.-Reference-Cited by-同舟云学术

Intravenous Artesunate Reduces Parasite Clearance Time, Duration of Intensive Care, and Hospital Treatment in Patients With Severe Malaria in Europe: The TropNet Severe Malaria Study: Figure 1.

Published:2015-07-17 Issue:9 Volume:61 Page:1441-1444
ISSN:1058-4838
Container-title:Clinical Infectious Diseases
language:en
Short-container-title:Clin Infect Dis.

Author:

Kurth Florian,Develoux Michel,Mechain Matthieu,Clerinx Jan,Antinori Spinello,Gjørup Ida E.,Gascon Joaquím,Mørch Kristine,Nicastri Emanuele,Ramharter Michael,Bartoloni Alessandro,Visser Leo,Rolling Thierry,Zanger Philipp,Calleri Guido,Salas-Coronas Joaquín,Nielsen Henrik,Just-Nübling Gudrun,Neumayr Andreas,Hachfeld Anna,Schmid Matthias L.,Antonini Pietro,Pongratz Peter,Kern Peter,Saraiva da Cunha José,Soriano-Arandes Antoni,Schunk Mirjam,Suttorp Norbert,Hatz Christoph,Zoller Thomas

Funder

Charité Universitätsmedizin Berlin and the Berlin Institute of Health

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Microbiology (medical)

Link

http://academic.oup.com/cid/article-pdf/61/9/1441/1190673/civ575.pdf

Reference11 articles.

1. Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial

2. Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial

3. Intravenous Artesunate for Severe Malaria in Travelers, Europe